Monte Rosa Therapeutics: H.C. Wainwright initiates coverage with buy rating and $25 target price
GLUE•H.C. Wainwright initiated coverage of Monte Rosa Therapeutics with a buy rating and a $25 target price.
Related News
Gold steadies as cooler US inflation data counters higher Treasury yields
GLD•
Avery Dennison schedules third-quarter earnings conference call webcast
AVY•
Fluor schedules third-quarter earnings conference call
FLR•
Stifel initiates coverage of Whitehawk Therapeutics with Buy rating and $9 price target
WHWK•
Blackstone Digital Infrastructure Trust cuts target price to $20 from $21
BXDC•